Evidence mapPaperPMID 40807232Full record

ReviewMolecules (Basel, Switzerland)2025

Neuroprotective Role of Omega-3 Fatty Acids: Fighting Alzheimer's Disease.

Mervin Chávez-Castillo, María Paula Gotera, Pablo Duran, María P Díaz, Manuel Nava, Clímaco Cano, Edgar Díaz-Camargo, Gabriel Cano, Raquel Cano, Diego Rivera-Porras and 1 more

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Nano-structured strategies in combatting neurodegeneration.Frontiers in bioengineering and biotechnology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mervin Chávez-CastilloEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela.ORCID 0000-0001-8511-0230
María Paula GoteraEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela.ORCID 0009-0004-3959-9820
Pablo DuranEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela.ORCID 0000-0002-8030-1780
María P DíazEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela.
Manuel NavaEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela.ORCID 0000-0001-9769-1693
Clímaco CanoEndocrine and Metabolic Diseases Research Center, School of Medicine, University of Zulia, Maracaibo 4001, Venezuela.
Edgar Díaz-CamargoFacultad de Ciencias Jurídicas y Sociales, Universidad Simón Bolívar, Cúcuta 540006, Colombia.
Gabriel CanoFreie Universität Berlin, Institut für Pharmazie, Königin-Luise-Strasse 2-4, 14195 Berlin, Germany.ORCID 0000-0003-2874-5330
Raquel CanoClínica General del Norte, Grupo de Estudio e Investigación en Salud, Barranquilla 080001, Colombia.ORCID 0000-0002-3692-9917
Diego Rivera-PorrasUniversidad de la Costa, Departamento de Productividad e Innovación, Barranquilla 080001, Atlántico, Colombia.ORCID 0000-0003-2169-3208
Valmore BermúdezUniversidad Simón Bolívar, Facultad de Ciencias de la Salud, Centro de Investigaciones en Ciencias de la Vida, Barranquilla 080001, Atlántico, Colombia.ORCID 0000-0003-1880-8887

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is one of the main causes of dementia, with an exponential increment in its incidence as years go by. However, since pathophysiological mechanisms are complex and multifactorial, therapeutic strategies remain inconclusive and only provide symptomatic relief to patients. In order to solve this problem, new strategies have been investigated over recent years for AD treatment. This field has been reborn due to epidemiological and preclinical findings that demonstrate the fact that omega-3 polyunsaturated fatty acids (ω-3 PUFAs) can be promising therapeutic agents because of their anti-inflammatory, antioxidant, and neurogenic-promoting activities, thus allowing us to classify these molecules as neuroprotectors. Similarly, ω-3 PUFAs perform important actions in the formation of characteristic AD lesions, amyloid-β plaques (Aβ) and neurofibrillary tangles, reducing the development of these structures. Altogether, the aforementioned actions hinder cognitive decline and possibly reduce AD development. In addition, ω-3 PUFAs modulate the inflammatory response by inhibiting the production of pro-inflammatory molecules and promoting the synthesis of specialised pro-resolving mediators. Consequently, the present review assesses the mechanisms by which ω-3 PUFAs can act as therapeutic molecules and the effectiveness of their use in patients. Clinical evidence so far has shown promising results on ω-3 PUFA effects, both in animal and epidemiological studies, but remains contradictory in clinical trials. More research on these molecules and their neuroprotective effects in AD is needed, as well as the establishment of future guidelines to obtain more reproducible results on this matter.

Indexed as

Alzheimer DiseaseFatty Acids, Omega-3Neuroprotective AgentsAnimalsHumansFatty Acids, Omega-3Neuroprotective AgentsAlzheimer’s diseaseanti-inflammatory activityneuroprotective moleculespolyunsaturated fatty acids

Identifiers

PMID40807232
PMCPMC12348196

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.